DB
MRNA icon

Dmitry Balyasny’s Moderna MRNA Stock Holding History

Dmitry Balyasny’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
+22,700
New +$1.17M ﹤0.01% 1944
2026
Q1 		– Sell
-38,800
Closed -$1.14M – 3283
2025
Q4 		$1.14M Buy
38,800
+17,800
+85% +$484K ﹤0.01% 2126
2025
Q3 		$542K Buy
+21,000
New +$586K ﹤0.01% 2366
2025
Q2 		– Sell
-411,900
Closed -$11.7M – 3158
2025
Q1 		$11.7M Buy
411,900
+396,500
+2,575% +$14.1M 0.02% 829
2024
Q4 		$640K Sell
15,400
-43,500
-74% -$2.08M ﹤0.01% 2105
2024
Q3 		$3.94M Buy
58,900
+14,200
+32% +$1.3M 0.01% 1373
2024
Q2 		$5.31M Buy
44,700
+24,700
+124% +$3.13M 0.01% 1141
2024
Q1 		$2.13M Buy
+20,000
New +$2.02M ﹤0.01% 1527
2023
Q3 		– Sell
-3,800
Closed -$462K – 2554
2023
Q2 		$462K Buy
+3,800
New +$507K ﹤0.01% 1875
2021
Q4 		– Sell
-192,000
Closed -$73.9M – 2478
2021
Q3 		$73.9M Sell
192,000
-590,700
-75% -$218M 0.31% 52
2021
Q2 		$184M Buy
782,700
+509,700
+187% +$91.1M 0.87% 7
2021
Q1 		$35.7M Buy
273,000
+168,000
+160% +$24.3M 0.18% 135
2020
Q4 		$11M Buy
+105,000
New +$10.6M 0.06% 412

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Dmitry Balyasny's MRNA Position: Q2 2026 in Review

Dmitry Balyasny increased its Moderna (MRNA) stake by 1,969% in Q2 2026, buying an estimated $5.29M and bringing the position to 107,418 shares worth $7.52M. The position accounts for 0.01% of the portfolio, ranked #1195.

Dmitry Balyasny first reported a position in MRNA in Q2 2019 and has held it in 16 quarters since. The position peaked at $72.3M in Q3 2023. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Dmitry Balyasny held 107,418 shares of Moderna worth $7.52M as of Q2 2026.
  • Dmitry Balyasny bought 102,227 Moderna shares in Q2 2026, an estimated $5.29M.
  • Moderna made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1195 holding.
  • Dmitry Balyasny first reported a position in Moderna in Q2 2019 and has held it in 16 quarters since.
  • Dmitry Balyasny's Moderna position peaked at $72.3M in Q3 2023.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.